Dr. Tse-Wen Chang, Chairman and Founder of Immunwork and T-E Meds, built his scientific career through National Tsing-Hua University, Harvard University, and the Massachusetts Institute of Technology (MIT), and went on to lead the development of Xolair, the world’s first anti-IgE drug—marking a groundbreaking milestone in the treatment of allergies and asthma.

After achieving remarkable success and reaching retirement, Dr. Chang embraced a new mission: to create world-class innovative drugs in Taiwan. He subsequently founded Immunwork and T-E Meds, continuing to dedicate himself to innovative drug development and advancing Taiwan’s biotechnology industry onto the global stage.

Chairman Interview Video:
https://youtu.be/6YYUnsgjrls

Related News Coverage:
https://www.ctwant.com/article/466825/
https://www.styletc.com/article/466821/
 
Back to the top